219 related articles for article (PubMed ID: 2949152)
1. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease.
Mazziotta JC; Phelps ME; Pahl JJ; Huang SC; Baxter LR; Riege WH; Hoffman JM; Kuhl DE; Lanto AB; Wapenski JA
N Engl J Med; 1987 Feb; 316(7):357-62. PubMed ID: 2949152
[TBL] [Abstract][Full Text] [Related]
2. Cerebral metabolism of glucose in benign hereditary chorea.
Suchowersky O; Hayden MR; Martin WR; Stoessl AJ; Hildebrand AM; Pate BD
Mov Disord; 1986; 1(1):33-44. PubMed ID: 2973557
[TBL] [Abstract][Full Text] [Related]
3. Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease.
Kuhl DE; Markham CH; Metter EJ; Riege WH; Phelps ME; Mazziotta JC
Res Publ Assoc Res Nerv Ment Dis; 1985; 63():199-209. PubMed ID: 3161165
[TBL] [Abstract][Full Text] [Related]
4. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
[TBL] [Abstract][Full Text] [Related]
5. Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease.
Kuhl DE; Metter EJ; Riege WH; Markham CH
Ann Neurol; 1984; 15 Suppl():S119-25. PubMed ID: 6234856
[TBL] [Abstract][Full Text] [Related]
6. Normal caudate glucose metabolism in persons at risk for Huntington's disease.
Young AB; Penney JB; Starosta-Rubinstein S; Markel D; Berent S; Rothley J; Betley A; Hichwa R
Arch Neurol; 1987 Mar; 44(3):254-7. PubMed ID: 2950844
[TBL] [Abstract][Full Text] [Related]
7. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method.
Kuhl DE; Metter EJ; Riege WH
Ann Neurol; 1984 May; 15(5):419-24. PubMed ID: 6610384
[TBL] [Abstract][Full Text] [Related]
8. Studies in persons at risk for Huntington's disease.
N Engl J Med; 1987 Aug; 317(6):382-4. PubMed ID: 2955223
[No Abstract] [Full Text] [Related]
9. Regression model for predicting dissociations of regional cerebral glucose metabolism in individuals at risk for Huntington's disease.
Clark CM; Hayden MR; Stoessl AJ; Martin WR
J Cereb Blood Flow Metab; 1986 Dec; 6(6):756-62. PubMed ID: 2947906
[TBL] [Abstract][Full Text] [Related]
10. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease.
Grafton ST; Mazziotta JC; Pahl JJ; St George-Hyslop P; Haines JL; Gusella J; Hoffman JM; Baxter LR; Phelps ME
Ann Neurol; 1990 Nov; 28(5):614-21. PubMed ID: 1979723
[TBL] [Abstract][Full Text] [Related]
11. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease.
Grafton ST; Mazziotta JC; Pahl JJ; St George-Hyslop P; Haines JL; Gusella J; Hoffman JM; Baxter LR; Phelps ME
Arch Neurol; 1992 Nov; 49(11):1161-7. PubMed ID: 1444883
[TBL] [Abstract][Full Text] [Related]
12. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
13. Brain glucose utilization in childhood Huntington's disease studied with positron emission tomography (PET).
De Volder A; Bol A; Michel C; Cogneau M; Evrard P; Lyon G; Goffinet AM
Brain Dev; 1988; 10(1):47-50. PubMed ID: 2967038
[TBL] [Abstract][Full Text] [Related]
14. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography.
Leenders KL; Frackowiak RS; Quinn N; Marsden CD
Mov Disord; 1986; 1(1):69-77. PubMed ID: 2973559
[TBL] [Abstract][Full Text] [Related]
15. Regional cerebral glucose metabolism in SLE chorea: further evidence that striatal hypometabolism is not a correlate of chorea.
Guttman M; Lang AE; Garnett ES; Nahmias C; Firnau G; Tyndel FJ; Gordon AS
Mov Disord; 1987; 2(3):201-10. PubMed ID: 3509775
[TBL] [Abstract][Full Text] [Related]
16. A method for comparing different procedures of estimating regional glucose metabolism using fluorine-18-fluorodeoxyglucose.
Clark CM; Grochowski EW; Ammann W
J Nucl Med; 1992 Jan; 33(1):157-60. PubMed ID: 1530965
[TBL] [Abstract][Full Text] [Related]
17. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease.
Weeks RA; Piccini P; Harding AE; Brooks DJ
Ann Neurol; 1996 Jul; 40(1):49-54. PubMed ID: 8687191
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography in the early diagnosis of Huntington's disease.
Hayden MR; Martin WR; Stoessl AJ; Clark C; Hollenberg S; Adam MJ; Ammann W; Harrop R; Rogers J; Ruth T
Neurology; 1986 Jul; 36(7):888-94. PubMed ID: 2940474
[TBL] [Abstract][Full Text] [Related]
19. Functional caudate imaging in symptomatic Huntington's disease: positron emission tomography versus single-photon emission computed tomography.
Martin WR; Hoskinson M; Kremer B; Maguire C; McEwan A
J Neuroimaging; 1995 Oct; 5(4):227-32. PubMed ID: 7579751
[TBL] [Abstract][Full Text] [Related]
20. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan.
Kuhl DE; Phelps ME; Markham CH; Metter EJ; Riege WH; Winter J
Ann Neurol; 1982 Nov; 12(5):425-34. PubMed ID: 6217782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
